Skip to main content
RegeneronPartnership

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Source: Autobound Signal API · 94 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

Regeneron extended its procurement agreement with BARDA to provide additional supply of the Ebola treatment Inmazeb valued at approximately $270 million through 2031.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb ® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers, and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA's original procurement of the treatment in 2020. Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S...

Keep reading with a free account

The rest of this article, and every signal for Regeneron, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Oct 26, 2026
Location
Tarrytown, New York, United States

Companies

  • Biomedical Advanced Research and Development AuthorityPartneraspr.hhs.gov

The full record

From the Signal API record

Details

Ticker
NASDAQ:REGN

Extraction

Confidence
95%
Detected
Oct 26, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/584d0cc4-be79-fc67-f914-c74d3277d6c7 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "584d0cc4-be79-fc67-f914-c74d3277d6c7",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-26T11:00:00+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/26/3387937/0/en/regeneron-extends-agreement-with-barda-to-provide-additional-supply-of-ebola-treatment-inmazeb-for-u-s-preparedness.html",
    "title": "Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness",
    "ticker": "NASDAQ:REGN",
    "excerpt": "Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb ® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers , and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA's original procurement of the treatment in 2020 . Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S...",
    "summary": "Regeneron extended its procurement agreement with BARDA to provide additional supply of the Ebola treatment Inmazeb valued at approximately $270 million through 2031.",
    "location": "Tarrytown, New York, United States",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1",
    "confidence": 0.95,
    "published_at": "2026-10-26T11:00:00Z",
    "location_data": [
      {
        "city": "Tarrytown",
        "state": "New York",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-26",
    "article_sentence": "Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S. government through 2031 and receive payment of approximately $270 million.",
    "related_company_name": "Biomedical Advanced Research and Development Authority",
    "related_company_domain": "aspr.hhs.gov"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.